Our basic business model is that we conduct drug development from the discovery and research stage to the early clinical stage in collaboration with research institutions and contracted service providers, and we partner with pharmaceutical companies from late development stage to commercialization.
Specifically, we grant development, manufacturing, and marketing rights to pharmaceutical companies, and in return we receive upfront, milestone and/or royalties. Depending on the disease area, we may execute late-stage clinical development, obtaining regulatory approval, and even marketing.
